This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Steinhubl, S. R. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Steinhubl, S. R. Articles by Lüscher, T. F. Social Bookmarking                   What's this?

Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

Division of Cardiology, University of Kentucky, Lexington, KY, USA, steinhubl{at}uky.edu

Juan J. Badimon

The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA

Deepak L. Bhatt

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA

Jean-Marc Herbert

Sanofi-Aventis Recherche, Cardiovascular-Thrombosis Research Department, Toulouse, France

Thomas F. Lüscher

University Hospital Zurich, Zurich, Switzerland

Recent advances in our understanding of cardiovascular disease have revealed that atherothrombotic events, such as myocardial infarction and ischemic stroke, are the end result of a complex inflammatory response to multifaceted vascular pathology. As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells). An increasing body of literature shows that inflammatory biomarkers can be used to predict atherothrombotic risk and that antiplatelet therapy may reduce the levels of these markers. Acetylsalicylic acid (ASA) has been attributed with reducing levels of the transcription factor nuclear factor B (NF-B), C-reactive protein, and soluble CD40 ligand, although the evidence relating to the latter two markers is conflicting. There is also substantial evidence that therapy with clopidogrel, a specific antagonist of the platelet P2Y₁₂ ADP-receptor, also leads to reductions in serum levels of CD40 ligand, C-reactive protein, P-selectin, and platelet—leukocyte aggregate formation. Beneficial effects of clopidogrel on inflammatory markers have been demonstrated across the spectrum of atherothrombotic disease (acute coronary syndrome patients, patients undergoing percutaneous coronary intervention (PCI), acute ischemic stroke patients, and those with peripheral arterial disease). Oral glycoprotein (GP) IIb/IIIa receptor antagonists, at doses that achieve moderate levels of receptor blockade, may paradoxically be associated with platelet-mediated pro-inflammatory effects. A similar phenomenon has been observed with intravenous GP IIb/IIIa antagonists in vitro, but most often at low doses, and data from clinical studies suggest that these agents may actually attenuate release of inflammatory mediators when administered at doses producing more complete receptor blockade.

Key Words: acetylsalicylic acid • clopidogrel • inflammation • platelet

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?